US EditionPublished • loading... • Updated
India moves closer to dengue vaccine as final trials underway
More than 10,000 volunteers participate in trials for DengiAll, which could provide affordable, long-term protection against all four dengue serotypes in a single dose.
- This year, Panacea Biotec began final Phase III trials of DengiAll in India, with results expected later this year.
- India has seen a surge in dengue cases and deaths since 2021, with over one million cases and at least 1,500 deaths; the WHO says rising temperatures and rainfall spread Aedes mosquitoes.
- Inside Panacea's research labs, Dr Priyanka Priyadarsiny described development steps from proof-of-concept to regulatory checks, with the candidate based on a strain from the US National Institutes of Health and developed by Panacea as the most advanced of three Indian firms with its own formulation and patent.
- In India, final approval would come from the Drug Controller General of India and WHO prequalification would be required for large-scale international use, with over 10,000 volunteers enrolled and rollout possible as early as next year if results are favorable.
- Most existing dengue vaccines require multiple doses, making DengiAll's single-dose potential notable, as it could protect people aged one to 60 and address scientific challenges from all four serotypes.
Insights by Ground AI
35 Articles
35 Articles
ABC FOX Montana+29 Reposted by 29 other sources
India moves closer to dengue vaccine as final trials underway
As dengue surges globally, an Indian vaccine candidate has entered the final stage of testing, raising hopes for one of the world's first single-dose shots against the deadly mosquito-borne disease.
·Missoula, United States
Read Full Article
Simin Akkter Naqvi, a 39-year-old professor, died in October 2024 due to the fact that Dengue died from an acute illness. While her husband, Shahnawaz Malik, remained to grow his only son, in India, is currently conducting the final phase of clinical studies for the first single-dose autohton vaccine, a hope [...]
·Romania
Read Full ArticleCoverage Details
Total News Sources35
Leaning Left5Leaning Right8Center8Last UpdatedBias Distribution38% Center, 38% Right
Bias Distribution
- 38% of the sources are Center, 38% of the sources lean Right
38% Right
L 24%
C 38%
R 38%
Factuality
To view factuality data please Upgrade to Premium
